CSN Login
Members Online: 7

hepatocellular carcinoma

annes449's picture
annes449
Posts: 15
Joined: Jun 2005

I don't know if our experience could possibly help someone else, but, I'm hoping that it might. On August 21st, 2006 my life partner was vibrant and healthy. His right shoulder hurt and he had had some heartburn for a couple of weeks. On August 25th, 2006 he was diagnosed with hepatocellular carcinoma and on September 19th, 2006 he died.

The first couple of weeks he was strong enough that we could have tried a clinical trial. The first couple of weeks it was easy to believe that we probably had six months or so to do something. We planned trips. We were going to take a cruise.

By the third week he was very ill.

I miss him very much.

offutt9's picture
offutt9
Posts: 90
Joined: Jan 2004

Hello!! I am so sorry to hear of your loss. Liver cancer has that way of sneeking up on you and you don't even know it is there; and if not found early enough, there is nothing anyone can do. I have angiosarcoma of the liver. Very rare, no cure, no treatment for it, no studies done for it. I am fighting for more to be done to find liver cancer early and more treatment options. It seems like you hear of all types of cancer except liver cancer and I want there to be more concern about it. I am sure your letter will help someone and I want you to know that you are in my prayers. If you want to talk, please feel free to email me. In Gods Love...Barbara

annes449's picture
annes449
Posts: 15
Joined: Jun 2005

http://www.newswire.ca/en/releases/archive/October2006/17/c8880.html

Jennerex Biotherapeutics today
announced an agreement with Green Cross Corp., South Korea for the development
and commercialization in Korea of JX-594, an oncolytic vaccinia virus for the
treatment of hepatocellular carcinoma (liver cancer) as the initial
indication...

This might turn out to be something.

Peace,
Anne

annes449's picture
annes449
Posts: 15
Joined: Jun 2005

Here is something:

..."Nov. 27, 2006--The HeptoVax trial is a phase II trial evaluating the safety and efficacy of GV1001 in advanced hepatocellular carcinoma ("HCC" or "liver cancer"). The trial will enrol patients from three centres in Spain, France and Germany...

..."GV1001: A cancer vaccine targeting telomerase GV1001 is a peptide vaccine that activates the immune system - primarily the immune system's T-cells - to recognize and kill cancer cells. GV1001 targets an enzyme called telomerase. Telomerase is seldom found in normal cell types but is over expressed in most cancer cells. In scientific circles, telomerase activity is considered a key factor in the process whereby cancer cells lose their normal mortality, which is a common feature for all cancers. In theory, GV1001 could therefore turn out to be a universal cancer vaccine and Pharmexa's development strategy for GV1001 reflects this.

source:

Pharmexa Has Started Phase II Trial in Liver Cancer with GV1001

Peace
Anne

annes449's picture
annes449
Posts: 15
Joined: Jun 2005

...only about one in ten (9 percent) of patients treated with colchicine developed HCC compared to more than one in four (29 percent) of untreated cirrhotic patients. In addition, if subjects developed HCC, patients who were treated with colchicine developed HCC later than those not treated with the drug. Colchicine chemoprevention delayed the diagnosis of HCC after cirrhosis onset by an average 72 months (222 months compared to 150 months). Furthermore, colchicine-treated patients survived longer than untreated patients...

http://www.biotech-weblog.com/50226711/colchicine_may_prevent_liver_cancer_in_viral_hepatitis_patients.php

Peace,
Anne

annes449's picture
annes449
Posts: 15
Joined: Jun 2005

This may be something one day:

... The researchers concluded: "This gene may serve as a potential target for pharmaceutical intervention of HCC."

Chen and colleagues published their study in Chinese Medical Journal (Potential role of novel hepatocellular carcinoma-associated gene IDD01 in promoting tumorigenesis of HepG2 cell line. Chinese Medical Journal, 2006;119(20):1709-14)...


Researchers from Zhengzhou University publish findings in hepatocellular cancer

Peace,
Anne

annes449's picture
annes449
Posts: 15
Joined: Jun 2005

Provectus Receives Orphan Drug Designation from FDA for Anti-Cancer Agent PV-10 for the Treatment Of Metastatic Melanoma

..."Pre-clinical animal studies have shown broad-spectrum applicability of the agent for selective ablation of a number of cancers, including melanoma, breast carcinoma, and hepatocellular carcinoma."...

Peace,
Anne

Subscribe with RSS
About Cancer Society

The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.

Copyright 2000-2014 © Cancer Survivors Network